Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing()

• This case reports the treatment of neuroendocrine carcinoma of the cervix with a PARPi based on NGS. • NGS reports have demonstrated somatic mutations BRCA in neuroendocrine carcinoma of the cervix. • The use of a PARPi in neuroendocrine carcinoma of the cervix has not been previously reported....

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Peter G., Sierk, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804835/
https://www.ncbi.nlm.nih.gov/pubmed/31649992
http://dx.doi.org/10.1016/j.gore.2019.100499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804835/
https://www.ncbi.nlm.nih.gov/pubmed/31649992
http://dx.doi.org/10.1016/j.gore.2019.100499

Ejemplares similares